BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...Treat impulsive aggression in patients with ADHD Phase III data 2H19 Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) SPN-812...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...NASDAQ:SUPN) Molindone Aggression in patients with ADHD Phase III data Mid-2019 Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) SPN-812...
BioCentury | Jan 4, 2019
Clinical News

Supernus' ADHD candidate meets in Phase III in adolescents

...Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) said on Dec. 20 that both doses of SPN-812 met the primary...
...to receive placebo or once-daily 200 or 400 mg oral SPN-812. On the primary endpoint, SPN-812...
...SPN-812 -- Study P304 in adolescents with ADHD. Supernus Pharmaceuticals Inc. (NASDAQ:SUPN), Rockville, Md. Product: SPN-812...
BioCentury | Dec 7, 2018
Clinical News

Supernus planning NDA for ADHD candidate following Phase III readouts

...Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) said SPN-812 met the primary endpoint in the Phase III P301 and...
...patients ages 6-11, respectively, to receive placebo or once-daily oral SPN-812. On P301's primary endpoint, SPN-812...
...respectively, of SPN-812 to treat adolescents with ADHD. Supernus Pharmaceuticals Inc. (NASDAQ:SUPN), Rockville, Md. Product: SPN-812...
BioCentury | Oct 17, 2016
Clinical News

SPN-812: Phase IIb data

...in 222 ADHD patients ages 6-12 showed that once-daily 200, 300 and 400 mg oral SPN-812...
...total score from baseline to week 8 vs. placebo. Specifically, 200, 300 and 400 mg SPN-812...
...mg SPN-812 for 5 weeks following a 3-week titration period. The 3 highest doses of SPN-812...
BioCentury | Oct 11, 2016
Clinical News

Supernus ADHD therapy meets in Phase IIb

...Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) said the three highest doses of SPN-812 met the primary endpoint of...
...inhibitor next year. The trial evaluated once-daily 100, 200, 300 and 400 mg doses of SPN-812...
...titration period in 222 children ages six to 12 with ADHD. The lowest dose of SPN-812...
BioCentury | Mar 14, 2011
Clinical News

SPN-812: Phase IIa data

...double-blind, placebo-controlled, U.S. Phase IIa trial in 52 adults with ADHD showed that thrice-daily oral SPN-812...
...5 weeks was well tolerated and met the primary endpoint of safety. On secondary endpoints, SPN-812...
...show statistical significance on any of the endpoints. Supernus Pharmaceuticals Inc. , Rockville, Md. Product: SPN-812...
BioCentury | Mar 12, 2011
Clinical News

Supernus reports adult ADHD data

...Supernus Pharmaceuticals Inc. (Rockville, Md.) said thrice-daily oral SPN-812 for five weeks was well tolerated and...
...safety in a Phase IIa trial to treat 52 adults with ADHD. On secondary endpoints, SPN-812...
...said the trial was not designed to show statistical significance on any of the endpoints. SPN-812...
BioCentury | Jul 19, 2010
Clinical News

SPN812: Phase IIa started

Supernus began a double-blind, placebo-controlled, U.S. Phase IIa trial in about 50 patients. Supernus Pharmaceuticals Inc. , Rockville, Md. Product: SPN812 Business: Neurology Molecular target: NA Description: NA Indication: Treat attention deficit hyperactivity disorder (ADHD) Endpoint:...
Items per page:
1 - 9 of 9